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T-cell development from hematopoietic progenitors depends on
multiple transcription factors, mobilized and modulated by intra-
thymic Notch signaling. Key aspects of T-cell specification network
architecture have been illuminated through recent reports de-
fining roles of transcription factors PU.1, GATA-3, and E2A, their
interactions with Notch signaling, and roles of Runx1, TCF-1, and
Hes1, providing bases for a comprehensively updated model of the
T-cell specification gene regulatory network presented herein.
However, the role of lineage commitment factor Bcl11b has been
unclear. We use self-organizing maps on 63 RNA-seq datasets from
normal and perturbed T-cell development to identify functional
targets of Bcl11b during commitment and relate them to other
regulomes. We show that both activation and repression target
genes can be bound by Bcl11b in vivo, and that Bcl11b effects
overlap with E2A-dependent effects. The newly clarified role of
Bcl11b distinguishes discrete components of commitment, resolv-
ing how innate lymphoid, myeloid, and dendritic, and B-cell fate
alternatives are excluded by different mechanisms.
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Tlymphocyte development from blood stem cells depends onthe regulatory inputs from a suite of transcription factors
needed by all T-cell types, as well as a set of factors that subdi-
vides mature T cells into different functional groups. Before
functional subdivision, a common core gene regulatory network
(GRN) guides multipotent precursors to generate committed
pro-T cells that will ultimately serve as progenitors for all T-cell
lineages. Commitment occurs in the thymus before the cells
acquire specific T-cell receptors (TCR) for antigen, and is driven
by a combination of extrinsic signals and intrinsic transcription
factor activity changes. This early T-cell GRN not only turns on
T-cell–specific genes but also coordinates early precursor pro-
liferation with stepwise renunciation of alternative developmental
potentials. We and others have found that the commitment pro-
cess concludes with the onset of expression of a zinc finger tran-
scription factor, Bcl11b (1–4). Here we identify the genes that are
immediately sensitive to Bcl11b activity, and integrate the Bcl11b
activation process into the context of the broader T-cell
specification GRN.
The thymic environment instructively promotes T-cell differ-
entiation of multipotent immigrant cells by presenting Notch
ligand Delta-like 4 (DLL4), and providing supportive cytokines
(Kit ligand, IL-7). The resulting Notch signaling drives precursors
to proliferate through a canonical series of stages [double negative
(DN) = CD4− CD8−; double positive (DP) = CD4+ CD8+]: from
Kithi DN1 (or early T-cell precursor, ETP), to DN2a, DN2b, and
DN3a stage (reviewed in ref. 5). If the precursors can begin TCR
expression successfully in DN3a, they continue through DN3b and
DN4 to DP, when the cells finally acquire complete TCR recog-
nition complexes (5, 6). Importantly, if individual T-cell precursors
in the ETP or DN2a stage are removed from thymic Notch li-
gands, they can still generate non-T cells, but from the DN2b stage
on, they can no longer do this unless genetically manipulated (1,
7). This transition defines “commitment.”
The robust change in potential from DN2a to DN2b is also
accompanied by dynamic transcription factor expression changes
(8, 9) At least 20 regulatory genes have expression patterns that
can be classed as “phase 1” (expressed in ETP and DN2a, then
down-regulated) or “phase 2” (turned on or significantly up-
regulated around commitment in DN2b) (5). To date, the most-
studied regulators of the phase 1 to phase 2 transition have been
Notch signaling, GATA-3, TCF-1, and E2A, and PU.1 as a
natural, endogenous “opponent” of developmental progression.
Of these, all are present in ETP and DN2a cells, and only Bcl11b
is up-regulated de novo during this commitment transition itself.
The activity of Bcl11b in commitment has had two aspects poorly
resolved to date. After commitment, Bcl11b seems to repress spe-
cific types of effector programs in T cells and innate lymphoid cells
(ILC), blocking genes associated with natural killer (NK)-like or
effector cytolytic T cells or with differentiation to specific IL-17–
producing subsets of invariant NK T cells (reviewed in refs. 6 and
10, 11). This effector-subtype blockade is important to support
memory CD8 cell function and regulatory T-cell differentiation, but
it does not explain why Bcl11b is important for T-lineage commit-
ment as a whole. Cells losing Bcl11b acutely long after commitment
activate an NK-cell like gene-expression profile (2, 12) or a pre-
cociously specialized T-cell profile (13), but not an immature gene-
expression profile like the one extinguished during commitment.
To resolve how Bcl11b is working, we have focused specifically
on the stages at the fulcrum of commitment to carry out a ge-
nome-wide RNA-seq analysis of the effects of Bcl11b deletion.
We have identified the most strongly influenced target genes in a
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de novo analysis of 63 RNA-seq datasets of wild-type as well as
perturbed developing T cells. We have resolved distinct subsets
of Bcl11b targets as they relate to the regulomes of other de-
velopmentally important transcription factors in T-cell develop-
ment, using self-organizing maps (SOM) (reviewed in ref. 14).
These SOM have long been used for analysis of gene-expression
(15, 16) and chromatin data (17) because they can resolve re-
lationships in very large datasets with large numbers of clusters,
and here they provide an elegant way to identify multiple, related
modules of Bcl11b targets with distinct roles in development. In
fact, many of the new Bcl11b target genes are unique to the peri-
commitment developmental context. We place these findings in
the context of an updated version of the T-cell specification
GRN model (5, 18–20) enhanced with recent insights into con-
nections between PU.1, Bcl11b, Notch signaling, and other cru-
cial factors: that is, GATA-3, TCF-1, Runx1, and the basic helix–
loop–helix factor E2A.
Results
T-Cell Specification GRN Transitions at Commitment: A Distinct
Context for Bcl11b. A model for the GRN that guides T-cell
commitment has been assembled over the last decade (18, 19)
but new linkages that control aspects of commitment timing have
now been illuminated. Recent reports have identified key mech-
anisms that make the transition from precommitment to com-
mitment into such a discontinuous, switch-like event. These
features are summarized in the revised and updated GRN model
shown in Fig. 1. The precommitment phase 1 period is defined by
strong expression of the B-cell–, dendritic-cell–, and myeloid-
cell–associated transcription factor PU.1 (encoded by Spi1, alias
Sfpi1), and stem-cell–associated regulatory genes that are acti-
vated prethymically, including Erg, Mycn, Hhex, Bcl11a, Gfi1b,
Mef2c, Lmo2, and Lyl1 (reviewed in ref. 5) (Fig. 1A). The most
important growth factor receptor sustaining this phase is enco-
ded by Kit. These genes all need to be down-regulated during
commitment. Meanwhile, Notch signaling turns on expression of
T-lineage genes, including Gata3 and Tcf7 (encoding TCF-1)
starting in the DN1 (ETP) stage, but these are not sufficient to
impose commitment. In contrast, Bcl11b, a phase 2 regulatory
gene, is transcriptionally silent until the late DN2a stage, and
then turns on abruptly. It is then expressed throughout the rest of
T-cell development and in mature T cells thereafter (Fig. 1B).
Both silencing of PU.1 and activation of Bcl11b are operationally
important for commitment (2–5, 21).
This updated model incorporates recent data on functional
impacts of E2A (22), on PU.1 and its interactions with Notch,
Myb, and GATA-3 (21, 23, 24), on Notch blockade of the my-
eloid program via Hes1 against Cebpa (25, 26), on GATA-3 and
its mutual antagonism with the B-cell program (27–30), and on
positive regulators of Bcl11b itself (1, 31). Discussed in detail in
SI Appendix, Supplementary Text, these results reveal two major
switch circuits. First, a mutual inhibition circuit between PU.1
and Notch, without mutual repression, buffers the intensity of
Notch signaling but restricts the lineage-diversion activity of
PU.1 if Notch signaling is present, while letting PU.1 support
genes linked to multipotentiality (21, 23) (Fig. 1A). This balance
defines the phase 1 pro–T-cell state, which is surprisingly per-
sistent in pro-T cells through days of proliferation. Second,
Bcl11b up-regulation depends on a stringently combinatorial
action of GATA-3, TCF-1 (encoded by Tcf7), Runx1, and Notch
signaling. Here, the most collaborative events appear necessary
to “prime” the locus during the DN1 phase, before actual tran-
scriptional activation in late DN2a phase (1). New results on
E2A targets are considered further below. Detailed review of the
operation of the network as a whole and evidence for specific
links are provided in SI Appendix, Supplementary Text.
The commitment event is tightly coupled with Bcl11b up-
regulation (Fig. 2A) (1), but the exact role of Bcl11b in this
process depends on the unique regulatory context, which is not
duplicated in any of the later T-cell contexts where Bcl11b works
(reviewed in ref. 10) nor in type 2 ILC, where it also has a role
(11, 32, 33). Until commitment (Fig. 1A), endogenous PU.1,
possibly other phase 1 genes, and even GATA-3 still represent
regulatory bridges to distinct alternative programs. Notch sig-
naling selectively intervenes in their actions to prevent alternative
lineage specification (21, 26, 34, 35), but still allows PU.1 to
sustain lymphoid-compatible phase 1 regulatory genes like
Bcl11a, Lmo2, and Mef2c (21) in phase 1 pro-T cells. Gene reg-
ulation at this stage can also reflect balances between different
factors competing to regulate common targets: for example, PU.1
and GATA-3 may compete, respectively, to repress or activate
Zfpm1, and Ets1, and to activate or repress Bcl11a (21, 23, 27).
This balance is tipped during commitment, with the silencing of
the phase 1 regulatory genes and down-regulation of Kit, but only
limited aspects of this process are understood. GATA-3, Runx1,
and TCF-1 (or its relative LEF-1) eventually play roles in si-
lencing expression of phase 1 regulatory genes encoding PU.1 and
Bcl11a during commitment, as demonstrated by gain- and loss-of-
function data (27, 36–39) (Fig. 1B). However, all of these factors
are present at comparable levels for multiple cell cycles before
commitment (examples shown in Fig. 2B). Thus, although the
precommitment and postcommitment states are clearly distin-
guished from each other, the exact role of rate-limiting compo-
nents like Bcl11b in triggering the transition between them has
not been fully defined.
Determination of Bcl11b Targets During Commitment. Cells failing
to turn on Bcl11b during commitment are arrested in vivo (13,
40) but proliferate well in vitro with strong Notch and cytokine
signals. In key respects the proliferating cells resemble DN2a
cells (3, 4) (DN2a* in Fig. 2A). They tend to differentiate to NK-
like cells if Notch signal intensity is reduced (2, 3). One prediction
is that Bcl11b should itself repress regulatory genes like Spi1
(PU.1) or Lyl1 that are sharply down-regulated in commitment
(Fig. 2B). Another prediction is that, if Bcl11b is important to
block access to the NK cell fate, then the NK-promoting genes it
represses might be expressed in T-cell precursors until the time
that Bcl11b is turned on. However, the actual results differ from
these predictions.
Conditional knockout (KO) Bcl11b DN2 cells and control
Bcl11b+ cells spanning the DN2a–DN3a interval plus two control
DP samples were generated for RNA-seq comparisons (Fig. 2C)
using two protocols (Fig. 2 D1 and D2 and SI Appendix, Sup-
plementary Methods). In most samples, Bcl11b was deleted before
its normal onset of expression, by introducing Cre into condi-
tional KO hematopoietic progenitor cells or wild-type controls
before T-cell development began (protocol I) (Fig. 2D1). We used
fetal liver-derived hematopoietic precursors and cultured control
and conditional KO cells in parallel in a well-characterized in vitro
T-cell differentiation system, with cytokines and OP9-DL1 or
OP9-DL4 stromal cells (3, 41) (SI Appendix, Fig. S1A). For pro-
tocol II (Fig. 2D2), we deleted Bcl11b from DN2b or DN3 cells
after commitment, usually deleting Bcl11b by CreERT2 activation
in vitro (2) in freshly isolated DN3 thymocytes. One other protocol
II sample pair used Lck-Cre deletion in vivo (SI Appendix, Sup-
plementary Methods). Both protocols generated characteristically
large, DN2a-like Bcl11b KO cells with high expression of Kit (SI
Appendix, Fig. S1A, days 9 and 12 and B, day 4). However, fetal-
derived cells that had lost Bcl11b before commitment could pro-
liferate extensively with high viability in OP9–DL4 coculture (3),
whereas adult-derived cells that had lost Bcl11b after commitment
grew poorly in the same conditions.
For RNA-seq analysis, multiple matched control vs. KO pairs,
additional Bcl11b KO samples, and additional controls were
sorted from in vitro cultures at corresponding developmental
stages, as well as three sets of adult samples with Bcl11b deleted
after commitment (Fig. 2C). Only cells with a DN2 or DN3
phenotype were sorted (SI Appendix, Fig. S1A, Inset) to exclude
any cells already transformed to NK cells. RNA-seq analysis (SI
Appendix, Fig. S2) showed that the targeted exon of Bcl11b was
efficiently deleted, and genes including Tnni1, Itga2b, Tyrobp,
Fcer1g, Cxcr5, Zbtb16, Nfil3, Id2, and Il2rb were up-regulated in
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the KO cells, whereas, e.g., Gbp4 and the Cd3 gene cluster were
down-regulated. Because of the dynamic developmental context
(Fig. 2D), there were variances in developmental progression
overall in different experiments (SI Appendix, Fig. S3A), as
shown by a panel of 90 indicator regulatory genes (SI Appendix,
Fig. S3B). Thus, although some gene-expression changes were
Fig. 1. GRNmodel of the early T-cell specification network using BioTapestry format (62). (A) Relationships among genes active in phase 1 (ETP to DN2a stages). Active
genes and connections are in color, inactive ones in gray. Both “AND” logic and “OR” logic relationships between inputs and target genes are included. Thick links:
validated direct effects. Regular links: perturbation evidence, at least indirect. Dashed links: weaker or uncertain effects. Circles at intersections: path branch points. The
off/on dichotomy in the display does not capture gradations in expression, and note that negative effects at many of the repressive nodes here represent “soft” damping
repression rather than silencing (see numbered notes below). A reciprocal antagonism circuit between Notch and PU.1 that maintains T-cell differentiation in phase 1 is
in the upper left quadrant. (B) Relationships among genes active in phase 2 (DN2b and later), after effects of Bcl11b are manifest and the phase 1 regulatory genes are
silenced. Numbers indicate specific connection properties as follows. 1: Notch signals and PU.1 activity modulate each other. Notch signaling inhibits a gene-specific
subset of PU.1 activities, here called “Notch-inhibited PU.1 activity”. 2: Repression by PU.1 is more severe if Notch signal is absent. 3, 5, 6, 8, and 9: Soft repression, i.e.,
indicated input limits the maximal activity of target gene but does not silence its expression. Also, 3: Inferred from response to forced PU.1 expression. 4: Complex
conditional and soft repressions: see SI Appendix, Supplementary Text. 5: Delayed activation in high IL-7. 6: Soft repression by Tcf7 short isoforms. 7: Nfil3 can activate Id2
but is unlikely to explain the transient Id2 in some DN2b cells. 8: Soft repression of distal Runx3 promoter. 9: Soft repression by E proteins. See SI Appendix, Supple-
mentary Text for details.
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seen in all Bcl11b KO samples, some were significant only in
particular types of samples: adult vs. fetal, protocol I vs. protocol
II, or where controls were more DN2b-like vs. more DN3a-like
(e.g., SI Appendix, Fig. S4: Kit, Cd7, Bcl11a). However, overall,
the expression changes observed were reproducible among
multiple independent KO-control sample pairs (e.g., Kit, Zbtb16,
Cpa3, Tnni1, Cd3g, Cd3d, Cd3e, all P < 10−2, n = 10) (SI Appendix,
Fig. S3C). To identify a “gold-standard” list of differentially
expressed genes, we grouped the paired-sample comparisons into
three pools and selected genes that showed significant up or down-
regulation (EdgeR, false-discovery rate < 0.05) in at least two of
the three separate pools (Dataset S1A; component lists in Dataset
S1 B and C; all genes differentially expressed in ≥one pool in
Dataset S1D). Of differentially expressed transcripts with known
protein-coding potential (omitting TCR loci, Gm and miR tran-
scripts), 77 were up-regulated significantly when Bcl11b was
knocked out and were thus presumably repressed by Bcl11b nor-
mally, whereas 22 lost expression and thus were Bcl11b-dependent
(Dataset S1A). Normal expression patterns of all these genes are
shown in SI Appendix, Fig. S5.
The high-confidence Bcl11b-dependent genes were more likely
to increase expression through normal commitment, whereas
Bcl11b-repressed genes tended to be down-regulated (SI Appen-
dix, Fig. S5A), consistent with the expression of Bcl11b itself (Fig.
2B). Several genes associated with initial TCR assembly were
notably Bcl11b-dependent in this developmental context, although
this has not been seen in later stages: that is, genes coding for CD3
signaling components and for Dntt, the terminal deoxynucleotidyl
transferase that helps in generating a highly diverse TCR reper-
toire (SI Appendix, Figs. S2 and S5C). We excluded Tcrb and Tcrg
loci from the gold-standard gene set because of annotation com-
plexity, but Dataset S1B suggests that Bcl11b may support these
differentiation-associated transcripts as well. In contrast, genes
that were repressed by Bcl11b (i.e., up-regulated in the KOs) fell
into several differently regulated groups, only a subset of them
phase 1-restricted. Purified DN3 cells from Bcl11bfl/fl mice that
did not express significant levels of Bcl11b-repressed targets
in vivo could be induced to express these genes by acute deletion
of Bcl11b in vitro, as confirmed by quantitative PCR (qPCR)
analyses (SI Appendix, Fig. S5B).
Context Dependence of Bcl11b Targets. Previous studies have ex-
amined Bcl11b deletion in later-stage thymocytes, CD4+ CD8+
DP cells (2, 12, 13), where an NK-like gene signature emerged.
Indeed, the Kyoto Encyclopedia of Genes and Genomes path-
way most highly enriched in our Bcl11b-repressed gold-standard
gene set was NK cell-mediated cytotoxicity (SI Appendix, Fig.
S6A), and multiple genes were shared with gene sets that dis-
tinguish ILC from T cells (42, 43). However, the gold-standard
set as a whole was distinct from top Bcl11b-regulated genes in
DP cells. A subset (24 of 77) of genes up-regulated in our Bcl11b
KO pro-T cells were affected similarly in Bcl11b KO DP cells, in
at least one of these other studies (2, 13) (SI Appendix, Fig. S6B
and Dataset S1E). However, the majority (53 of 77) of Bcl11b-
repressed gold-standard genes from DN2/3 cells were not iden-
tified in DP cell analyses (e.g., Cd7, Cpa3, Kit, Tnni1, and
Zbtb16) (compare SI Appendix, Figs. S2 and S4). Moreover, only
2 of 22 Bcl11b-dependent genes in DN2-3 cells were affected in
DP cells (SI Appendix, Fig. S6C and Dataset S1F). Thus, the
genes that Bcl11b must keep silent are more consistent across
developmental stages than those that it may help to activate.
When examining many hematopoietic cell samples from the
ImmGen consortium (9, 44), we found that the gold-standard
Bcl11b-dependent genes often peaked in expression at DN3a
stage (SI Appendix, Fig. S7A, star), whereas expression patterns
of the Bcl11b-repressed genes were notably diverse across mul-
tiple hematopoietic lineages (SI Appendix, Fig. S7B). Many
Bcl11b-repressed genes (Tnni1, Il2rb, Zbtb16, Id2, Cxcr5) did not
-2
0
2
4
6
8
10
PU
.1
Ly
l1
Ru
nx
1
E2
A
Tc
f1
2
Ga
ta
3
Tc
f7
Bc
l1
1b
Zb
tb
16
N
fil
3
Id
2
Lo
g(
2)
 R
PK
M
FLDN1
FLDN2a
FLDN2b
ThyDN3
ThyDP
ETP/DN1 DN2a
DN2a*
DN2b
NK or
ILC?
DN3a DP
Bcl11b
KO
Commitment
Bcl11b up
PU.1 down
TCR gene
rearrangement
ETP/DN1 DN2a DN2b DN3a
CA
D1 Protocol I Protocol IID2
B
RNA-seq datasets
Sorted samples: wildtype ETP, DN2a, DN2b, DN3, DP; wildtype DN2b, DN3 Cre 
controls; Bcl11b acutely deleted DN2a*; wildtype DN2a +/- PU.1 antagonists
calculate expression levels with Rsem
FPKM matrix
train SOM
Metacluster
Metacluster-trait Specific hypothesis
test on matched pair
SOM unit 
coordinate
Gene(s) in the 
unit
(x0, y0) Gene1, Gene4…
(x0, y1) Gene2, Gene3…
... ...
(xm, yn) GeneN
SOM
Metacluster
Metacluster SOM unit coordinate
Metacluster0 (x0, y0), (x0, y1)… 
Metacluster1 (x0, y3), (x1, y2)…
... ...
MetaclusterN (xm-1, yn), (xm, yn)…
ETP/DN1 DN2a
DN2a* DN2a*
DN2b
or Bcl11b
KO
Cre
control
or Bcl11b KO        
Cre
control
Gene Sample1 Sample2 ... SampleM
Gene1 fpkm11 fpkm12 ... fpkm1m
Gene2 fpkm21 fpkm22 ... fpkm2m
Gene3 fpkm31 fpkm32 ... fpkm3m
Gene4 fpkm41 fpkm42 ... fpkm4m
... ... ... ... ...
GeneN fpkmn1 fpkmn2 ... fpkmnm
FPKM matrix
Fig. 2. The T-cell developmental system and experimental design. (A) Stages in T-cell development and branch point affected by loss of Bcl11b. For definition
of markers, see ref. 5. (B) Expression levels of important regulatory factors in early T cells, as measured by RNA-seq. (8). (C) Brief workflow of RNA-seq data
processing and SOM analysis. (D) Comparison of two deletion protocols for Bcl11bf/f samples to test the impact of Bcl11b loss in early T development. (D1) In
protocol I, Cre is introduced before T-cell development is started, by retroviral transduction in precursors that then develop as indicated on OP9-DLL1 stroma.
(D2) In protocol II, Cre is activated in adult thymic DN3 cells after commitment, either by Lck-Cre activity in vivo or by tamoxifen induction of Cre-ERT2 in
purified DN3 thymocytes in vitro, then culturing cells for 3–4 more days before analysis (SI Appendix, Supplementary Methods).
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simply continue expression from uncommitted phase 1 progeni-
tors, but were either up-regulated from ETP–DN2a levels, or
else activated dramatically de novo if Bcl11b were absent.
Bcl11b Binding to Target Genes in Vivo. ChIP and sequencing
(ChIP-seq) showed clear Bcl11b binding to sites around positive
and negative regulation targets in DN3 cells (Fig. 3A and SI
Appendix, Fig. S8 A–G). Bcl11b specifically occupied sites at
most if not all gold-standard loci, including Zbtb16, Tnni1, Dntt,
and Cd3d (ChIP-PCR in Fig. 3B). Sites were often in open
chromatin at positively regulated loci but also at closed or closing
sites in many repressed targets (SI Appendix, Fig. S8 A–C). Such
sites are candidates for mediators of direct regulation.
Global Picture of Bcl11b Effects in the Context of Early T-cell
Development. To relate the genes that Bcl11b controls to the
global context of T-cell development, we used all of the RNA-
seq data in our 63 samples to generate a SOM, clustering gene-
expression patterns in all our samples into a large toroidal 40 ×
60-unit map. This is a format that is particularly well-suited for
clustering high-dimensional datasets first into units of groups of
genes that have nearly identical expression profiles among all
samples (clusters), then placing similarly regulated units near each
other on the map geographically in >one dimension (meta-
clusters). Importantly, the 2D mapping relates clusters by more
than one criterion of similarity. SOM analysis thus enabled us to
group the whole transcriptome into 300 metaclusters based on
fine-grained similarities of regulation not only in development but
also under perturbation (17) (Fig. 3C and SI Appendix, Supple-
mentary Methods and Fig. S9A).
The gene-expression patterns defined a complex landscape (SI
Appendix, Fig. S9A) in which changes in expression of different
groups of genes were shown by coordinated increases or de-
creases in signal between stages from particular metacluster re-
gions (Fig. 3 C–G and SI Appendix, Fig. S9B and Dataset S2).
Phase 1-specific genes were concentrated in a subset of meta-
cluster regions (blue in Fig. 3C and region B in SI Appendix, Fig.
S9B), while later-expressed genes could be mapped to another
subset of regions (red in Fig. 3C and region A in SI Appendix,
Fig. S9B). Patterns of expression of the eigengenes for specific
metaclusters, across all our samples, are shown in SI Appendix,
Fig. S10. For example, PU.1 (Sfpi1, Spi1) is in metacluster 112
(region B, in SI Appendix, Fig. S9B), one whose expression is
significantly down-regulated in DN2b and later samples (SI Ap-
pendix, Fig. S10A). Other phase 1-specific regulatory genes, such
as Bcl11a, map nearby (in metacluster 212) (region B in SI Ap-
pendix, Fig. S9B and expression in SI Appendix, Fig. S10B). In
contrast, the phase 2-specific genes, including Bcl11b itself (in
metacluster 26) (SI Appendix, Fig. S10D), are in the upper-right
cluster region up-regulated in DN2b T cells (region A in SI Ap-
pendix, Fig. S9B).
The SOM analysis clearly showed that Bcl11b deletion up-
regulated expression of genes in two distinct metacluster neigh-
borhoods with different relationships to normal development
(Fig. 3D and SI Appendix, Fig. S9B, regions C1 and C2). When
the DN2b vs. DN1 fold-change map is compared with the
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Fig. 3. Bcl11b targets and SOM analysis of their organization in distinct regulomes. (A) ChIP-seq shows Bcl11b binding in DN3 cells to a repression target, Id2
(Upper), and a Bcl11b-dependent target, Dntt (Lower). Two independent samples each of Bcl11b ChIP and control (1% of input) are shown aligned to the
mm9mouse genome. Red arrows: primary transcription units of Id2 and Dntt, respectively. [Scale bars: 20 kb (Upper), 100 kb (Lower).] Vertical scales: 0.02–1.0 fpm.
(B) Specific Bcl11b binding in vivo to target gene regulatory sites. ChIP for Bcl11b was analyzed by qPCR for enrichment of candidate regulatory sequences of
Zbtb16, Tnni1, Dntt, and Cd3d. No binding was seen to Igk, Gapdh, and Il4 negative control sites. Averages from three independent experiments are shown
(error bars: SD). (C) Fold-change SOM, color-coded to show normal gene-expression changes from the DN1 to DN2b stage. Red regions contain genes up-
regulated in DN2b pro-T cells. Blue regions: genes down-regulated. For delimitation of SOM metaclusters, see SI Appendix, Fig. S9A. Four representative
metaclusters—112, 168, 212, and 26 (SI Appendix, Fig. S10)—are labeled with arrows. The heatmap shows fold-change of average fragments per kilobase of
transcript per million mapped reads (FPKM) within each unit, in logarithmic scale. (D) Fold-change SOM comparing Bcl11b KO DN2 and control DN2-3 pro-T
cells. Red units are up-regulated after Bcl11b KO. (E) Fold-change SOM comparing PU.1 antagonist-expressing and control DN2 pro-T cells. Red units are up-
regulated in PU.1 antagonist-expressing cells, blue units are repressed. (F) Genes up-regulated in E2A−/− DN2 pro-T cells from ref. 22, mapped onto the SOM
metaclusters. Note high similarity with pattern of red (enriched) clusters in D. (G) Genes down-regulated in E2A−/− DN2 cells, mapped onto the SOM. Note
overlap with certain cluster regions that are blue (depleted) in D. (H) Heatmap of hypothesis tests. The metaclusters with significant enrichment of the
differentially expressed genes are displayed in red, and those that are significantly depleted are in blue. The color scale corresponds to the P value of the
enrichment/depletion of differential genes in each metacluster. Dashed lines shown the location of the four representative metaclusters. An expanded
version is in SI Appendix, Fig. S12A.
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Bcl11bKO vs. control fold-change map (Fig. 3 C and D), one
region of genes enhanced in the Bcl11b KO overlapped with
genes with phase 1-biased expression (Fig. 3 C and D; region C1
substantially overlapping region B in SI Appendix, Fig. S9B).
These metaclusters include or adjoin the clusters containing
most of the signature phase 1 regulatory genes (Dataset S2A),
identifying the specific immature properties that are perpetuated
in Bcl11b KO cells. However, the other salient region (region C2
in SI Appendix, Fig. S9B) consisted of genes up-regulated de
novo in Bcl11b-deficient DN2-like cells. This includes genes as-
sociated with NK function and ILC/NK fate, like Nfil3 and
Zbtb16 themselves (metacluster 168) (SI Appendix, Fig. S10C).
Thus, through distinct sets of genes Bcl11b loss retards aspects of
T-cell differentiation and promotes acquisition of a new fate.
Explaining Bcl11b Impact on Development.
No global epistasis with PU.1. Although Bcl11b KO cells perpetu-
ated some aspects of the phase 1 state, including high Kit ex-
pression (DN2a* in Fig. 2A), few phase 1 signature transcription
factor genes themselves were specifically up-regulated in Bcl11b
KOs (although Bcl11a down-regulation tended to be delayed)
(SI Appendix, Fig. S4). Bcl11b KO cells also seemed normally
competent to express T-cell–specifying regulatory genes (Dataset
S2B). In general, they often up-regulated Gata3 (metacluster
214), while specifically activating the distal promoter isoform of
Runx3 (metacluster 188) (browser view shown in SI Appendix,
Fig. S11). Bcl11b KO effects were not mimicked by Notch in-
hibition, as measured by short-term γ-secretase inhibition (GSI)
in DN2a or DN2b cells, shown by the lack of impact on similar
metaclusters in this SOM analysis (SI Appendix, Fig. S12A).
Therefore, we tested two other ways that Bcl11b might normally
advance the T-cell gene regulatory program: by suppression of
phase 1 regulator effectiveness or enhancement of E protein
activity.
During commitment, the trajectories of Bcl11b and Spi1
(PU.1) expression cross, one up-regulated as the other is down-
regulated (1, 45) (Fig. 2B). To test whether these act as mutual
antagonists, we directly compared Bcl11b KO effects with those
of an acutely acting PU.1 obligate repressor in DN2a cells
(PU.1–ENG), which we had used as a dominant negative to
identify genes that depend on wild-type PU.1 (23). SOM analysis
identified a supercluster of genes that were severely down-reg-
ulated by the obligate PU.1 repressor (Fig. 3E, lower right; near
regions B and C1 in SI Appendix, Fig. S9B), a SOM placement
consistent with expression in ETP–DN2a, as expected if driven
by high PU.1 activity (compare with Fig. 3C). To see if these
PU.1-dependent genes were up-regulated by Bcl11b deletion, we
used trait-enrichment heat maps to compare these perturbations
on each SOM gene metacluster (Fig. 3H; complete version in SI
Appendix, Fig. S12A). In fact, only rare metaclusters showed
opposite responses to the PU.1 antagonist and to Bcl11b de-
letion (Fig. 3H) (e.g., metacluster 212). In the gold-standard
gene set, the overlaps were limited and extraordinarily symmet-
rical, showing no bias toward cooperative or antagonistic rela-
tionships between Bcl11b and PU.1 (SI Appendix, Fig. S12B and
Dataset S3). Interestingly, some genes under dual control of
Bcl11b and PU.1 were repressed by both (e.g., Il2rb and Zbtb16,
and more weakly, Kit) (23). Thus, neither Bcl11b nor PU.1 is
globally epistatic to the other. Instead, they provide mostly or-
thogonal inputs to the pro–T-cell program.
Strong network intersection with E2A. In contrast, Bcl11b deletion
effects had strong overlap with reported effects of E2A deletion
in DN2-stage pro-T cells (22) (SI Appendix, Fig. S12C). The
gold-standard gene responses to Bcl11b loss (Dataset S4A)
overlapped greatly with the effects of E2A deletion (SI Appendix,
Table S4B), highly biased to respond in the same direction (Fig.
3 F and G; compare with Fig. 3D; numbers given in SI Appendix,
Fig. S12C) (P = 3E-04 by χ2 test). Most of the overlap was be-
tween genes up-regulated in both Bcl11b KOs and E2A KOs
(Dataset S4C). There was less overlap between Bcl11b-
dependent genes and genes affected in any way by E2A KO, but
the overlap again was in genes dependent on both (Dataset S4D).
Interestingly, this linked Bcl11b with the repressive effects of
E2A even more than with E2A’s activating effects (46–48). Thus,
Bcl11b appears to cooperate with E2A in its effects to promote
developmental progression and to suppress innate-cell like gene
expression, as summarized in the model shown in Fig. 4.
GRN Roles of Bcl11b as a Regulator of Cell Fate. Bcl11b showed
surprisingly few specific cross-regulatory effects on other tran-
scription factor-coding genes previously implicated in the progres-
sion from phase 1 to phase 2 in T-cell development. Metaclusters
up-regulated in Bcl11b KO cells (Dataset S2) contained some
phase 1 regulatory genes that we verified to respond consistently to
Bcl11b, although not meeting gold-standard criteria, including
Bcl11a, Nrarp, and Jup (SI Appendix, Figs. S3C and S4), and distal
promoter transcripts of Runx3 (SI Appendix, Fig. S11). Bcl11a is
associated with progenitor and B-cell fates, whereas Nrarp and
distal Runx3 are expressed in NK cells. Metaclusters up-regulated
in Bcl11b KO pro-T cells (Dataset S2) also contained later-acting
T-cell regulators Gata3 and Lmo4, also verified by inspection to be
frequently but weakly up-regulated (SI Appendix, Fig. S3C). These
regulators are expressed not only in later T cells but also highly in
ILC2 cells (Gata3) and in invariant NK T cells, ILC2, and ILC3
cells (Lmo4), and are also up-regulated in E2A KO samples (22).
Thus, Bcl11b during commitment could be damping the non-T
lineage roles of these factors.
The most striking effects of Bcl11b on other regulators were to
maintain silence of genes seemingly extrinsic to the T-cell pro-
gram. These include regulatory factor and cytokine receptor
genes Zbtb16, Nfil3, Pou2af1, and Il2rb. These are genes without
obvious drivers within the rest of the known program, and are
normally poorly expressed, if at all, before Bcl11b is expressed
(compare with SI Appendix, Fig. S2, DN1). Whereas most of
these genes have at least some baseline expression, some sources
of positive regulation are logically required even for targets that
Fig. 4. GRN model of roles of Bcl11b and E2A in the T-cell specification
gene network. BioTapestry plots use conventions as in Fig. 1. Targets shown
are from the gold-standard list and additional genes validated as shown in SI
Appendix, Figs. S2, S3C, S4, and S11, and represent sets with shared and
unshared responses to Bcl11b and E2A. They include genes with likely impact
on the rest of the network that are concentrated in Bcl11b-repressed met-
aclusters in the SOM analysis. Additional genes with similar expression
properties identified by SOM cluster membership are noted in the text.
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normally have undetectable expression (e.g., Tnni1). The Bcl11b
KO effects thus logically imply a cryptic positive regulator for
them (Fig. 4).
Discussion
Bcl11b is a critical component of the T-lineage commitment
machinery, but the target genes it regulates during the commit-
ment process itself have not been globally defined until now. Here
we have shown that Bcl11b exerts highly stage-specific positive
effects on genes involved in TCR complex assembly and more
complex negative effects on a range of target genes, some only
during commitment and others at later stages as well, involved in
effector response and cellular identity. Bcl11b has many binding
sites around both positive and negative regulatory targets, which
can be extensively mined in future detailed characterization for
insights into its activating and repressive modes of action.
Bcl11b plays a key repressive role during commitment that
affects two large groups of genes under distinct baseline patterns
of regulation. The first group comprises genes, including the key
growth factor receptor gene Kit, that are most expressed during
phase 1 and turned off after Bcl11b is induced (Fig. 4, phase
1-specific expression). Some, though not all of these genes are
only open to Bcl11b regulation during the DN2 to DN3 transition,
and later may be permanently silenced. The second group con-
sists of genes that are normally not activated to substantial levels
at all during the phase 1 stages. Curiously, these are highly
enriched for genes used in NK cells, ILCs, and innate-like T cells,
including the powerful regulatory genes Id2, Zbtb16, and Nfil3 (6,
42, 49–55). Many of these genes, especially NK-associated genes,
require continual Bcl11b action to keep them silent later (Fig. 4,
zero or low normal expression). Many other genes are expressed
earlier and silenced during commitment. Why are these genes not
expressed before Bcl11b is activated? The fact that they are silent
before Bcl11b turns on could imply that they need another positive
driver that gains in net activity during T-cell specification in par-
allel with Bcl11b itself. Is this truly a new function? Some of these
targets, like Zbtb16 and Il2rb, could have positive regulators that
are masked before Bcl11b is turned on, as phase 1 regulator PU.1
also represses them (23) (Fig. 1A). It could thus be loss of PU.1-
dependent restraint in phase 2 that creates a “need” for Bcl11b to
“take over” the repressive role. Further analysis will be required to
relate individual Bcl11b occupancy sites at these loci to specific
activating or repressive functions, which could ultimately indicate
how Bcl11b works to antagonize their activators. However, the
fact that Bcl11b is not needed to repress these genes until Bcl11b
itself is activated suggests that Bcl11b acts on these genes in classic
incoherent feed-forward circuit architecture.
The role of Bcl11b is mostly orthogonal to the role of PU.1, and it
does not appear to be a direct repressor of most phase 1 tran-
scription factor-coding genes. Many of its phase 1-associated targets
encode cell surface markers, signaling, and cell biology components.
However, the convergence of Bcl11b actions with E2A actions at
the DN2a/b stages is striking. The mode of action does not appear
to require coordinated binding to DNA, because the peaks identi-
fied here on dual E2A–Bcl11b target genes (Fig. 3A and SI Ap-
pendix, Fig. S8) do not coincide substantially with peaks bound in
DN3 cells by E2A (46). Does Bcl11b amplify or sustain E protein
action mainly by blocking expression of Id2, the E protein antago-
nist? Id2 is crucial for the regulatory states of NK cells and ILCs,
but it cannot fully account for Bcl11b’s role in the phase 1 to phase
2 transition, as there is no decrease in Id2 expression then (Fig. 2B).
Also, Id2 is very easily up-regulated with any reduction of Bcl11b
level, suggesting that Bcl11b may only weakly repress this gene.
Recently, too, the type 2 ILC lineage has been shown to depend on
Bcl11b as well as on Id2 (11, 32, 33), proving that the two can be
coexpressed. Most genes de-repressed in Bcl11b KOs (Datasets S1
and S2) are more typical of NK, ILC1, and ILC3 cells than of ILC2
cells (54, 56), suggesting that low levels of Bcl11b may block these
alternatives while still allowing Id2 expression in ILC2 cells. Thus,
additional Bcl11b-repressed genes besides Id2 may be equally im-
portant in excluding innate fates.
Up-regulation of Zbtb16, Nfil3, Id2, and Il2rb in Bcl11b-
deficient cells provides both growth support and identity func-
tions for NK and ILC fates outside of the conventional αβ T-cell
pathway (43, 53, 57, 58). Many Bcl11b KO cells also up-regulate
the phase 1-specific Notch-negative feedback regulator, Nrarp,
which is also highly expressed in NK cells. These genes are not all
up-regulated uniformly in all Bcl11b KO cases, however. For
example, Zbtb16 was up-regulated in our DN2–DN3 KO samples
made by both protocols I and II (SI Appendix, Fig. S2 and
Dataset S1 A–C), but more strongly in fetally derived cells and
not in DP KO cells (2, 13; but see ref. 59). In contrast to Zbtb16,
Nfil3 was more strongly up-regulated in protocol II and in DP
cells, again suggesting underlying differences in their needs for
positive regulators that could promote alternatives to T-cell fate.
The fate alternatives restricted by Bcl11b have further differ-
ences from those controlled by PU.1. Pro-T cells in phase 1
overtly express multiple myeloid-associated genes regulated by
PU.1 (23), even as Notch signaling restrains others. However,
these are silenced during commitment and most will never be
expressed by T cells again. In contrast, many of the ILC response
genes that Bcl11b represses are normally expressed much later
by mature T cells during postthymic immune effector responses,
despite the cells’ committed status (SI Appendix, Fig. S7). Thus,
it may be physiological for these Bcl11b-repressed genes to be
latently primed for activation during T-cell specification. If so,
then another way to see Bcl11b’s role at the DN2b stage is that it
imposes a temporal delay between the time that these genes
could be initially specified for activity (in DN2b pro-T cells) and
the time that mature TCR-αβ T cells (their much later descen-
dants) will be allowed to deploy them. As we and others have
discussed previously (60, 61), the timing of deployment of the
effector response gene subnetwork distinguishes αβ-TCR+ T
cells, γδ-TCR+ T cells, and ILCs more profoundly than the ac-
tual effector response networks themselves. Some of the targets
we see up-regulated in Bcl11b KOs in fact include genes specific
for certain γδ lineages (e.g., Cd163l1, Tnni1, and certain Tcrg
transcripts). Thus, Bcl11b appears to control the conditionality
of access to effector activation gene subnetworks even more than
progression within a single canonical T-cell pathway itself.
The role of Bcl11b in commitment thus reflects a different
mechanism of innate/adaptive divergence than the control of access
to myeloid fates. Unlike PU.1, Zbtb16 and Nfil3 are not normally
part of the phase 1 regulatory state. However, considerable overlap
between T-cell and ILC programs (6), including use of Runx3 and
GATA-3, suggests ways that the T-cell specification process itself
can generate mechanisms to prime these genes for expression. Loss
of Bcl11b can allow levels of both Gata3 and Runx3 to rise.
Maintaining repression then appears to depend on E protein, di-
rectly or indirectly, as well as Bcl11b. Thus, in the T-cell GRN, the
most dynamically regulated T-cell factor collaborates with the most
unchanging one to establish and preserve the committed state.
Methods
See SI Appendix, Supplementary Methods for details.
Animals and Cell Preparations. Bcl11b conditional KO mice, C57BL/6 (B6)
controls, and PLBD [(B6,129).Bcl11bfl/fl;ROSA26-CreERT2 (2)] mice with or without
a ROSA26R-eYFP Cre-reporter gene were bred and used as sources of control
and Bcl11b-deficient T-cell precursors as previously described (3, 27) (SI Appendix,
Supplementary Methods and Dataset S5). B6.Lck-Cre mice were obtained from
Taconic Laboratories. Both KO and control cells were Cre-treated and usually
sorted based on Cre-induced YFP+ phenotype as well as DN2a/b phenotype. RNA
was prepared and sequenced as described previously (8). Animals were bred and
maintained under specific pathogen-free conditions in our colony at the Cal-
ifornia Institute of Technology under protocols approved by the Institutional
Animal Care and Use Committee.
Data Analysis. RNA-seq and ChIP-seq fastq files were aligned and processed,
and the data matrix submitted to SOM analysis (17), as described in detail in
SI Appendix, Supplementary Methods. The gold-standard gene set was de-
fined by EdgeR comparisons of eight KO and control sample pairs (SI Ap-
pendix, Supplementary Methods and Datasets S1 B and C and S5).
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Gene Network Construction. BioTapestry v. 7.1.0 (www.biotapestry.org) soft-
ware (62) was used as described in SI Appendix, Supplementary Methods.
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